

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**CanSino Biologics Inc.**  
**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6185)**

**REMOVAL OF STOCK MARKER**

Reference is made to the announcement of the CanSino Biologics Inc. (the “**Company**”) dated May 24, 2022 (the “**Announcement**”) with respect to the approval granted by the Stock Exchange on May 20, 2022 for the dis-application of the Relevant Rules to the Company. Unless otherwise defined, capitalized terms used herein shall have the same meanings as defined in the Announcement.

Further to the Announcement, the Company wishes to advise investors that the “B” marker will cease to be affixed to the Company’s Chinese and English stock short name from May 31, 2022.

By order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, May 26, 2022

*As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.*